The MAGOH/hnRNPH1 axis promotes alternative splicing-derived soluble PD-L1 generation and attenuates PD-L1 blockade efficacy in gastric cancer
Abstract Despite the clinical success of PD-1 blockade, the therapeutic efficacy of PD-L1 blockade in gastric cancer (GC) remains limited. Soluble PD-L1 (sPD-L1) has been proposed to function as a decoy that sequesters anti-PD-L1 antibodies, potentially contributing to therapeutic resistance. Our previous study identified an exon 5/6-skipping PD-L1 splice variant, designated PD-L1-v1, as an important source of sPD-L1 in GC. We also found that MAGOH is highly expressed in GC and participates in alternative splicing regulation. Here, we demonstrate that PD-L1-v1 acts as a soluble decoy that limits PD-L1 blocker binding to membrane-bound PD-L1 on tumor cells, thereby impairing the antitumor efficacy of PD-L1 blockade. Mechanistically, MAGOH upregulates hnRNPH1 expression, primarily by enhancing its mRNA stability, and promotes hnRNPH1-dependent exon5/6 skipping of PD-L1 pre-mRNA, thereby facilitating PD-L1-v1 and sPD-L1 generation. These findings reveal a previously unrecognized mechanism of resistance to PD-L1 blockade and highlight the MAGOH/hnRNPH1 axis as a potential strategy for improving immunotherapy efficacy in GC.
Authors
- Donghui Zhou (ORCID: https://orcid.org/0000-0002-1937-9888)
- Cheng Chen (ORCID: https://orcid.org/0000-0003-2105-8191)
- Yuntong Li (ORCID: https://orcid.org/0009-0004-1036-1966)
- Kecheng Jiang
- Shanshan Yu
Institutions
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Cell Communication and Signaling
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1186/s12964-026-03379-w
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China